FARE', ELENA
FARE', ELENA
Universita' degli Studi di MILANO
Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer : a Retrospective Comparison of Efficacy and Safety Profiles
2019 C. Vernieri, M. Prisciandaro, M. Milano, M.S. Cona, C. Maggi, M. Brambilla, A. Mennitto, C. Fabbroni, E. Farè, S. Cresta, L. Celio, G. Mariani, G. Bianchi, G. Capri, F. de Braud
Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma : a systematic review and meta-analysis of patient outcomes
2015 P. Giannatempo, T. Greco, L. Mariani, N. Nicolai, S. Tana, E. Farè, D. Raggi, L. Piva, M. Catanzaro, D. Biasoni, T. Torelli, S. Stagni, B. Avuzzi, M. Maffezzini, G. Landoni, F. De Braud, A.M. Gianni, G. Sonpavde, R. Salvioni, A. Necchi
Immunohistochemistry to enhance prognostic allocation and guide decision-making of patients with advanced urothelial cancer receiving first-line chemotherapy
2015 A. Necchi, P. Giannatempo, B. Paolini, S. Lo Vullo, M. Marongiu, E. Farè, D. Raggi, N. Nicolai, L. Piva, M. Catanzaro, D. Biasoni, T. Torelli, S. Stagni, M. Maffezzini, A.M. Gianni, F. De Braud, L. Mariani, G. Sonpavde, M. Colecchia, R. Salvioni
Quality of life and pain control following laparoscopic retroperitoneal lymph node dissection in early-stage nonseminoma.
2015 N. Nicolai, E. Bianchi, I. Donati, C. L’Acqua, C. Brunelli, D. Biasoni, M. Catanzaro, S. Stagni, L. Piva, T. Torelli, A. Necchi, D. Raggi, P. Giannatempo, E. Faré, M. Colecchia, M. Langer, C. Borreani, R. Salvioni
Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer
2014 A. Necchi, L. Mariani, P. Giannatempo, D. Raggi, E. Farè, N. Nicolai, L. Piva, D. Biasoni, M. Catanzaro, T. Torelli, S. Stagni, M. Maffezzini, G. Pizzocaro, F.G. De Braud, A.M. Gianni, R. Salvioni
PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer : an open label, single-group, phase 2 trial
2014 A. Necchi, P. Giannatempo, L. Mariani, E. Farè, D. Raggi, M. Pennati, N. Zaffaroni, F. Crippa, A. Marchianò, N. Nicolai, M. Maffezzini, E. Togliardi, M.G. Daidone, A.M. Gianni, R. Salvioni, F. De Braud
Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes
2013 A. Necchi, N. Nicolai, L. Mariani, D. Raggi, E. Farè, P. Giannatempo, M. Catanzaro, D. Biasoni, T. Torelli, S. Stagni, A. Milani, L. Piva, G. Pizzocaro, A.M. Gianni, R. Salvioni
Persistent CD30 expression by embryonal carcinoma in the treatment time course: prognostic significance of a worthwhile target for personalized treatment
2013 P. Giannatempo, B. Paolini, R. Miceli, D. Raggi, N. Nicolai, E. Faré, M. Catanzaro, D. Biasoni, T. Torelli, S. Stagni, L. Piva, L. Mariani, R. Salvioni, M. Colecchia, A.M. Gianni, A. Necchi